WHO re­ports rise of an­tibi­otic-re­sis­tant gon­or­rhea

BioSpectrum (Asia) - - Who News -

Data from 77 coun­tries show that an­tibi­otic re­sis­tance is mak­ing gon­or­rhea, a com­mon sex­u­ally-trans­mit­ted in­fec­tion, much harder to treat. The WHO Global Gono­coc­cal An­timi­cro­bial Sur­veil­lance Pro­gramme (WHO GASP), mon­i­tors trends in drug-re­sis­tant gon­or­rhoea. WHO GASP data from 2009 to 2014 find wide­spread re­sis­tance to ciprofloxacin, in­creas­ing re­sis­tance to azithromycin, and the emer­gence of re­sis­tance to the cur­rent last-re­sort treat­ment: the ex­tended-spec­trum cephalosporins (ESCs) oral ce­fixime or in­jectable cef­tri­ax­one.

Cur­rently, in most coun­tries, ESCs are the only sin­gle an­tibi­otic that re­main ef­fec­tive for treat­ing gon­or­rhoea. But re­sis­tance to ce­fixime, and more rarely to cef­tri­ax­one, has now been re­ported in more than 50 coun­tries. As a re­sult, WHO is­sued up­dated global treat­ment rec­om­men­da­tions in 2016 ad­vis­ing doc­tors to give 2 an­tibi­otics: cef­tri­ax­one and azithromycin. The Drugs for Ne­glected Dis­eases ini­tia­tive (DNDi) and WHO have launched the Global An­tibi­otic Re­search and Devel­op­ment Part­ner­ship (GARDP) to ad­dress this is­sue. GARDP’s mis­sion is to de­velop new an­tibi­otic treat­ments and pro­mote ap­pro­pri­ate use, so that they re­main ef­fec­tive for as long as pos­si­ble, while en­sur­ing ac­cess for all in need. One of GARDP’s key pri­or­i­ties is the devel­op­ment of new an­tibi­otic treat­ments for gon­or­rhoea.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.